What does the US FDA approval of trilaciclib mean for oncologists and their patients?

Written by Jared Weiss (UNC’s Lineberger Comprehensive Cancer Center)

tumor, cancer, cancer cells

In this interview we speak with Jared Weiss from UNC’s Lineberger Comprehensive Cancer Center (NC, USA) about challenges associated with treating small cell lung cancer (SCLC) and his thoughts on what the recent US FDA approval of trilaciclib, for the treatment of extensive SCLC patients to reduce chemotherapy-induced bone marrow suppression, could mean for SCLC patients. Please introduce yourself and tell us about your career to date. My name is Jared Weiss.  I’m a medical oncologist and cancer researcher at UNC’s Lineberger Comprehensive Cancer Center where I focus on lung cancer and head and neck cancer. Clinically, I am most...

To view this content, please register now for access

It's completely free